This website uses cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.

Aurum Biosciences

Aurum Biosciences

Aurum Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics and diagnostics in areas of unmet clinical need. Its patented ABL-101 platform technology represents the first major advancement in the management of acute stroke patients in the past 20 years. The technology is being developed in other clinical indications such as inflammatory conditions, oncology, cardiovascular conditions, spinal cord injury and dementia.

Aurum Biosciences is a 2015 spin-out company of NHS Greater Glasgow and Clyde, University of Glasgow and InnoScot Health.


© Copyright 2024, InnoScot Health.

All rights reserved.

InnoScot Health works in partnership with NHS Scotland to identify, protect, develop and commercialise new innovations from healthcare professionals. Registered Number: SC 236303. Registered address: 272 Bath Street, Glasgow, G2 4JR
Office Address / Deliveries: Suite 203, The Pentagon Centre, 36 Washington Street, Glasgow, G3 8AZ